放疗联合免疫检查点阻断治疗III期不可切除非小细胞肺癌的研究进展

中华放射肿瘤学杂志 Pub Date : 2019-11-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2019.11.016

Rutian Li, Zhengfei Zhu, Lifeng Wang, Jing Yan, Yingtzu Yan, Baorui Liu

{"title":"放疗联合免疫检查点阻断治疗III期不可切除非小细胞肺癌的研究进展","authors":"Rutian Li, Zhengfei Zhu, Lifeng Wang, Jing Yan, Yingtzu Yan, Baorui Liu","doi":"10.3760/CMA.J.ISSN.1004-4221.2019.11.016","DOIUrl":null,"url":null,"abstract":"Chemoradiation has been the standard treatment of stage Ⅲ unresectable non-small cell lung cancer (NSCLC) for a long period of time. However, the clinical efficacy of chemoradiation has not been significantly improved in recent two decades. In the past 2-3 years, the role of immune-checkpoint inhibitors in metastatic NSCLC has been persistently strengthened. Moreover, the synergistic effect between radiotherapy and immune-checkpoint blockade has been conformed in pre-clinical and clinical studies. Recent clinical trials have demonstrated that the combination of radiotherapy and immune-checkpoint blockade has been proven to be more effective in the treatment of stage Ⅲ unresectable NSCLC. In this article, the latest clinical studies since 2017 regarding the application value of this combined treatment of stage Ⅲ unresectable NSCLC were summarized. \n \nKey words: \nLung neoplasm/radiotherapy; Immune-checkpoint blockade; Research progress","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"28 1","pages":"872-875"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress on application of the combination of radiotherapy and immune-checkpoint blockade in treatment of stage III unresectable non-small cell lung cancer\",\"authors\":\"Rutian Li, Zhengfei Zhu, Lifeng Wang, Jing Yan, Yingtzu Yan, Baorui Liu\",\"doi\":\"10.3760/CMA.J.ISSN.1004-4221.2019.11.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chemoradiation has been the standard treatment of stage Ⅲ unresectable non-small cell lung cancer (NSCLC) for a long period of time. However, the clinical efficacy of chemoradiation has not been significantly improved in recent two decades. In the past 2-3 years, the role of immune-checkpoint inhibitors in metastatic NSCLC has been persistently strengthened. Moreover, the synergistic effect between radiotherapy and immune-checkpoint blockade has been conformed in pre-clinical and clinical studies. Recent clinical trials have demonstrated that the combination of radiotherapy and immune-checkpoint blockade has been proven to be more effective in the treatment of stage Ⅲ unresectable NSCLC. In this article, the latest clinical studies since 2017 regarding the application value of this combined treatment of stage Ⅲ unresectable NSCLC were summarized. \\n \\nKey words: \\nLung neoplasm/radiotherapy; Immune-checkpoint blockade; Research progress\",\"PeriodicalId\":10288,\"journal\":{\"name\":\"中华放射肿瘤学杂志\",\"volume\":\"28 1\",\"pages\":\"872-875\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华放射肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2019.11.016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2019.11.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

长期以来，放化疗一直是Ⅲ期不可切除非小细胞肺癌(NSCLC)的标准治疗方法。然而，近二十年来，放化疗的临床疗效并没有显著提高。在过去的2-3年中，免疫检查点抑制剂在转移性NSCLC中的作用不断加强。此外，在临床前和临床研究中，放疗与免疫检查点阻断之间的协同作用已得到证实。最近的临床试验表明，放疗和免疫检查点阻断联合治疗Ⅲ期不可切除的非小细胞肺癌更有效。本文对2017年以来该联合治疗Ⅲ期不可切除NSCLC应用价值的最新临床研究进行综述。关键词:肺肿瘤/放疗;Immune-checkpoint封锁;研究进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress on application of the combination of radiotherapy and immune-checkpoint blockade in treatment of stage III unresectable non-small cell lung cancer

Chemoradiation has been the standard treatment of stage Ⅲ unresectable non-small cell lung cancer (NSCLC) for a long period of time. However, the clinical efficacy of chemoradiation has not been significantly improved in recent two decades. In the past 2-3 years, the role of immune-checkpoint inhibitors in metastatic NSCLC has been persistently strengthened. Moreover, the synergistic effect between radiotherapy and immune-checkpoint blockade has been conformed in pre-clinical and clinical studies. Recent clinical trials have demonstrated that the combination of radiotherapy and immune-checkpoint blockade has been proven to be more effective in the treatment of stage Ⅲ unresectable NSCLC. In this article, the latest clinical studies since 2017 regarding the application value of this combined treatment of stage Ⅲ unresectable NSCLC were summarized. Key words: Lung neoplasm/radiotherapy; Immune-checkpoint blockade; Research progress

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.